The results of adjuvant radiotherapy in endometrial carcinoma

Korcum, Aylin Fidan; Duman, Evrim; Aksu, Gamze

doi:10.1080/09513590903225341

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall survival at 2, 5, and 10 years was 95%, 84%, and 79.4%, respectively, these results are consistent with others reported in the literature [28]. After a mean followup of 49 months, 338 patients (82%) were still alive without disease, 13 (3%) were alive with disease, and 85 (21%) were dead by the time this analysis was done.…”

Section: Discussionsupporting

confidence: 90%

“…The policies for the use of radiotherapy have changed compared with trials, where EBRT + VBT were obligated for every patient operated with endometrial carcinoma [13, 14]. With more common use of lymphadenectomy during surgery, the value of adjuvant pelvic RT given to lymph-node negative areas has become questioned, and now patients from the intermediate risk group seem to benefit only from adjuvant VBT [15, 16, 28]. The inclusion criteria for this group vary slightly from trial to trial.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective

et al. 2012

View full text Add to dashboard Cite

Aim. To analyze the clinical characteristics and treatment outcomes in patients with endometrial carcinoma treated in a Latin American institute with emphasis in patients receiving adjuvant radiotherapy. Methods. A total of 412 patients with endometrial carcinoma admitted to our hospital between 1998 and 2008 were evaluated, retrospectively. The mean age was 55 years (28–87). Two hundred seventy patients received RT following surgery. Stage distribution was as follows: 221 patients (54%) stage I, 86 patients (21%) stage II, and 103 patients (24.5%) stage III and 2 patients (0.5%) stage IVA. Results. Overall survival rate was 95% at 2 years, 84% at 5 years, and 79% at 10 years. By the end of followup, 338 patients (82%) were disease-free, and 13 (3%) were alive with disease. Univariate and multivariate analyses identified age, grade, serosal and adnexial involvement as significant predictors for overall survival. Conclusion. The results of our study suggests that early-stage, low-grade endometrial cancer with no risk factors should not receive external beam radiotherapy, intermediate risk patients should receive only vaginal vault brachytherapy, and the use of chemotherapy with radiotherapy for patients high-risk and advanced-stage carcinoma the addition of radiotherapy is associated with a better survival being an effective therapeutic option.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective

et al. 2012

View full text Add to dashboard Cite

show abstract

The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma

Dane¹,

Bakir²

1970

Afr H. Sci.

View full text Add to dashboard Cite

Background: We investigated the relationship between myometrial invasion and the prognostic factors on overall and progression free survival in endometrial carcinoma.Methods: 122 cases operated with endometrial cancer were included into the study. Progression-free survival and overall survival were evaluated according to degree of myometrial invasion. We also investigated the relationship between myometrial invasion and prognostic factors. Results: The 5- year progression-free survival rate was 90 % in stage I, 66 % in stage II, 32 % in stage III and 60 % in stage IV. The 5- year overall survival rate was 95 % in stage I, 89 % in stage II, 49 % in stage III and 30 % in stage IV. The progression free survival and overall survival for patients with more than 50 % myometrial invasion were detected 67 % at 58 months and 66 % at 60 months, respectively. The clinicopathological variables that significantly correlated with myometrial invasion of more than 50 % were as follows: pelvic lymph node metastasis (p: 0,00029-OR: 11.2), cervical stromal invasion (p: 0008-OR:7.9), LVSI (p< 0.0001-OR: 16.5).Conclusion: The depth of myometrial invasion is one of the most important prognostic indicators and determinants of therapy in endometrial cancer. Keywords: Endometrial carcinoma; Progression free survival; Overall survival; Prognostic factors.

show abstract

The results of adjuvant radiotherapy in endometrial carcinoma

Abstract: The results of our study suggests that early stage, low-grade endometrial cancer with no serosal involvement is associated with a better survival and adjuvant radiotherapy is a well tolerated and effective therapeutic option.

Cited by 2 publications

References 29 publications

Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective

Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective

The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma

Contact Info

Product

Resources

About